PRIMARY STUDY
A new treatment paradigm for sickle cell disease leg ulcers: Topical cannabis-based medicines
Key Findings: In this review of a patient with a 12-year history of non-healing leg wounds due to sickle cell disease, topical cannabis-based medicines (TCBMs) were applied daily and the wounds healed in an average of 43.3 days.
Type of Study: Clinical Trial
Study Sample Size: 1
Study Result: Positive
Research Location(s): Canada
Year of Pub: 2020
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Tetrahydrocannabinolic Acid (THC-a)
Phytocannabinoid Source: Unspecified
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, PPAR - Gamma, GPCR, TRPs, PPARs, CB2 agonist
Ligands Studied: Serotonin
Route of Administration: Topical
Citation: Maida V, et al. A new treatment paradigm for sickle cell disease leg ulcers: Topical cannabis-based medicines. Exp Dermatol. 2021; 30:291-293. doi: 10.1111/exd.14256
Authors: Maida V, Shi RB, Fazzari FGT, Zomparelli LM
